Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

Precious Cells Group appoints David Huse in expansion push

December 15, 2015 Medical Communications, Research and Development Stem cells, precious cells group

Precious Cells Group, a UK-based international provider of stem cell storage and related technologies, has announced the appointment of commercial …
Appointment
personal-95715_640

Mirror. Signal. Merger. How to deal with a pharma takeover

December 14, 2015 Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
Feature
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015 Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
News
roche_scientists

Which are pharma’s most innovative companies?

December 11, 2015 Medical Communications, Research and Development GSK, Roche, research and development

It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
Feature
AZ_scientist

AstraZeneca deal to delve into the secretome

December 11, 2015 Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome

MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
News
xarelto

Regulators to probe Bayer’s Xarelto trial results

December 10, 2015 Medical Communications, Research and Development

Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
News
cindy_whitehead

‘Female Viagra’ CEO leaves company

December 10, 2015 Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma

Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
Appointment
mackayjimeson_1345198498_140

Two new corporate affairs leads appointed at Pfizer

December 9, 2015 Medical Communications Pfizer, corporate affairs

Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads. The company recently restructured its global pharma business …
Appointment
mark_forbes_irving

Former Quintiles director joins IDEA Pharma as MD

December 9, 2015 Medical Communications, Sales and Marketing IDEA Pharma, Mark Forbes Irving

IDEA Pharma has appointed Mark Forbes Irving as managing director. With over 20 years’ industry experience, the new managing director joins …
Appointment
Logos

New regulatory submissions for AbbVie and Novo Nordisk

December 4, 2015 Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart

AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
News
john_harris

OBN appoints Dr John Harris as chief executive

December 4, 2015 Medical Communications, Sales and Marketing OBN

OBN, the membership organisation supporting the UK’s emerging life sciences companies, has appointed Dr John Harris as its new chief executive, replacing …
Appointment
Teva image

Teva strips $1 billion worth of assets to clear Allergan deal

December 4, 2015 Medical Communications, Sales and Marketing Allergan, Teva, acquisitions, divestments, mergers

Teva Pharmaceuticals is thought to be in the process of stripping nearly $1 billion worth of assets to address antitrust …
News
Novartis image

NICE backtracks on Novartis Farydak decision

December 4, 2015 Medical Communications, Sales and Marketing Farydak, NICE, Novartis, panobinostat

NICE has reversed its earlier decision to reject the Novartis drug Farydak as an NHS treatment for people with multiple …
News
zometa

Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015 Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025